Drug Profile


Alternative Names: Arxxant; LY 333531

Latest Information Update: 15 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Takeda
  • Class Eye disorder therapies; Indoles; Maleimides
  • Mechanism of Action Protein kinase C beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic macular oedema; Diabetic nephropathies; Diabetic neuropathies; Diabetic retinopathy; Heart failure

Most Recent Events

  • 09 Jun 2016 Children's Hospital Medical Center and The Christ Hospital plan a phase I/II trial for Heart failure in USA (PO) (NCT02769611)
  • 08 Apr 2011 Novartis completes acquisition of Alcon
  • 26 Aug 2010 Alcon has been acquired by Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top